Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine

Next Previous
X
Search
Trial Profile

A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 19 Jun 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dihydroergotamine mesilate (Primary)
  • Indications Migraine; Migraine with aura; Migraine without aura
  • Focus Registrational; Therapeutic Use
  • Acronyms SUMMIT
  • Sponsors Satsuma Pharmaceuticals

    • Most Recent Events

    • 13 Jun 2024 According to a Satsuma Pharmaceuticals media release, company will present abstracts describing efficacy and safety data from this trial at the American Headache Society's (AHS) 66th Annual Scientific Meeting in San Diego, CA from Thursday, June 13 to Sunday, June 16, 2024.
    • 15 Jun 2023 According to a Satsuma Pharmaceuticals media release, data from this study selected for presentation at the American Headache Societys (AHS) 65th Annual Scientific Meeting; Full abstracts are now available on the AHS website and will be published in the journal Headache.
    • 18 May 2023 According to a Satsuma Pharmaceuticals media release, results from this trial were announced in November 2022 and subsequently in December 2022.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top